Novel Diagnostic Sequencing System for HIV Resistance Testing

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 2R44AI074232-03A1
Agency Tracking Number: R44AI074232
Amount: $2,952,955.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA10-123
Timeline
Solicitation Year: 2011
Award Year: 2011
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
34 Bear Hill Rd., Waltham, MA, -
DUNS: 170777770
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 JERZY OLEJNIK
 (781) 354-3354
 jerzy@intelligentbiosystems.com
Business Contact
 STEVEN GORDON
Phone: (781) 466-8050
Email: sgordon@intelligentbiosystems.com
Research Institution
 Stub
Abstract
DESCRIPTION (provided by applicant): As of 2008 the CDC estimated that there were approximately 1.1 million persons in the U.S. infected with HIV- 1 and about 56,000 new cases are diagnosed each year. During the mid-to-late 1990s, advances in treatment slowed the progression of HIV to AIDS and related deaths. Unfortunately, the treatment often leads to the emergence of drug resistant mutants of HIV-1. The knowledge of the HIV-1 variants present in a patient is extremely important to effectively plan diseasemanagement. It is estimated that about 10% of HIV-1 infections in the US is caused by drug resistant HIV-1 variants and current guidelines recommend HIV-1 resistance genotyping before therapy and to monitor therapy effectiveness. However, current tests that rely on conventional DNA sequencing methods do not detect low-levels (lt 20%) of drug-resistant strains and therefore may not provide the necessary diagnostic information for effective treatments. The goal of this proposal is to develop a highly sensitive comprehensive and cost-effective system for HIV-1 resistance genotyping based on IBS' high-speed massively parallel DNA sequencing system (RESIQ ). IBS' sequencing-by-synthesis system is based on the use of cleavable fluorescent nucleotides with reversible terminator technology. These features enable efficient removal of fluorescent signals and sequencing of repeats. During Phase II, a prototype sequencing instrument prototype will be constructed and extensive validation of the prototype using validatedclinical samples will be performed. Dr. Daniel Kuritzkes, an expert in the HIV-1 treatment and resistance will serve as a consultant for this project. Successful accomplishment of the Phase II project will result in the development of highly effective andcomprehensive RESIQ system for rapid, sensitive cost-effective HIV-1 drug resistance genotyping. 0 PUBLIC HEALTH RELEVANCE: The proposed research is aimed at the development of a high-sensitivity sensitive, cost-effective HIV-1 resistance genotyping system which is powered by massively parallel DNA sequencing by synthesis (SBS). Compared to current technology based on DNA sequencing, the Intelligent Bio-Systems' approach will be able to rapidly detect low levels (1-20%) of multiple drug resistant HIV-1 variants in patient's plasma. The major application of the SBS-GEN HIV-1 genotyping product will be the detection of the presence, at levels 1-20%, of the viral population with drug-resistance. The SBS-GEN HIV-1 genotyping system will be used in patients undergoing anti-retroviral drug therapy to monitor its effectiveness, changing the treatment regimen, or patients newly diagnosed with HIV-1 infection. 0

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government